Search Articles — Sudonull

Search Results

From other projects

LAG-3 agonist IMP761: first clinical success in autoimmune diseases

https://ymaho.com/lag-3-agonist-imp761-first-clinical-success-in-autoimmune-diseases

LAG-3 agonist IMP761 has shown clinical efficacy in suppressing T-cells for the first time. Learn about the revolution in treating autoimmune diseases without side effects. Read more.

Enspryng reduced the risk of relapses in MOGAD by 68%

https://ymaho.com/enspryng-reduced-the-risk-of-relapses-in-mogad-by-68

Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.

Tzield approved for children from 1 year: delaying type 1 diabetes

https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes

FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.

Saphnelo Pen approved by FDA: treating lupus at home

https://ymaho.com/saphnelo-pen-approved-by-fda-treating-lupus-at-home

FDA approved Saphnelo subcutaneous pre-filled pens for lupus treatment. Patients can self-administer the drug without visiting a clinic. Learn about the breakthrough in therapy.

CAR-T therapy for lupus: FDA approval 2026

https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026

Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.

Trending Now